POPULARITY
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trial Presenters:James Davis, PharmD, BCOPClinical Pharmacy Specialist, Malignant HematologyMUSC Hollings Cancer CenterAssistant ProfessorMUSC College of PharmacyCharleston, South CarolinaVictoria Nachar, PharmD, BCOPClinical Pharmacist Specialist, HematologyUniversity of Michigan Rogel Cancer CenterAnn Arbor, MichiganLink to full program: https://bit.ly/3H2EcSX
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL. Vose provides an overview of the current treatment landscape for patients with MCL, including Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies. Vose also discusses mechanisms of resistance to BTKi and the impact on patient outcomes. This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.
La Dra. Claudia Agudelo, hematóloga adscrita a la Fundación Santa Fe en Bogotá, Colombia, nos habla sobre los estudios más relevantes del Congreso Anual de la Asociación Europea de Hematología 2025 celebrado en Milán, Italia.Los trabajos comentados son:ALLG BM12 CAST (abstract S103)JNJ-90014496 (abstract S239)AMLSG 21-13 (abstract S149)BRUIN CLL-321 (abstract PS2282)AXI-CEL (real-world study) (abstract S237)Referencias:Curtis D., Purtill D., Lewis C., y cols. (S103) A phase 3 randomised trial of post-transplant cyclophosphamide for gvhd prophylaxis in matched sibling donor peripheral blood stem cell transplantation: the ALLG BM 12 cast trial.Patel K., Rhodes J., Mounljoy L., y cols. (S239) A global phase 1b study of jnj-90014496, a cd19/cd20 bi-specific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large b-cell lymphoma (LBCL).Döhner H., Weber D., Saadati M., y cols. (S149) Phase 3 study of intensive chemotherapy with or without dasatinib in patients with core binding factor acute myeloid leukemia – final analysis of the AMLSG 21-13 trial.Ghia P., Rossi D., Ferrant E., y cols. (PS2282) Patient reported outcomes from BRUIN CLL-321: a randomized phase 3 trial comparing pirtobrutinib to idelalisib/rituximab or bendamustine/rituximab in covalent BTKi pretreated CLL/SLL.Lee D., Kambhampati S., Bobillo M. S., y cols. (S237) Real-World effectiveness and safety outcomes among key subgroups of second-line (2L) axicabtagene ciloleucel (axi-cel) for patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL).Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. EHA® es una marca registrada de la European Hematology Association.Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.
Drs. Brander and Cohen discuss an ongoing debate in the management of CLL about BTK and BCL2 inhibitor combinations in the frontline treatment of CLL. Is it better to combine BTK and BCL2 inhibitors, or to start with one or the other as monotherapy?
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.
La Dra. Nidia Paulina Zapata Canto, hematóloga adscrita al Instituto Nacional de Cancerología en la Ciudad de México, presenta un análisis de los estudios más relevantes del año 2024 en el ámbito de la hematología. Mieloma múltiple DREAMM-7: Estudio fase III, global, aleatorizado 1:1, y abierto en el cual se comparó la eficacia y seguridad de belantamab mafodotina, bortezomib y dexametasona (BVd) vs. daratumumab, bortezomib y dexametasona (DVd) en pacientes con mieloma múltiple que habían presentado progresión después de al menos una línea previa de tratamiento. Leucemia linfocítica crónica EPCORE CLL-1: Estudio fase Ib/II, multicéntrico, abierto que evaluó la seguridad y eficacia de epcoritamab. Se incluyeron pacientes con LLC CD20+ refractario/recaída que requerían tratamiento y ≥2 líneas de tratamiento sistémico previas, incluido el tratamiento con o intolerancia a un BTKi. Leucemia mieloide crónica ASC4FIRST: Estudio fase III, aleatorizado que comparó asciminib con todos los inhibidores de tirosina cinasa estándar en el tratamiento de la leucemia mieloide crónica en fase crónica recién diagnosticada. Se analizaron los resultados primarios de eficacia, así como datos adicionales de seguridad y tolerabilidad de asciminib frente a cada TKI a partir del análisis primario con el corte de datos de la semana 48. Linfoma del manto ECOG-ACRIN EA4181: Estudio fase III, aleatorizado 1:1:1 que comparó 1. Bendamustina, rituximab y citarabina en dosis altas 2. Bendamustina, rituximab, citarabina en dosis altas y acalabrutinib y 3. Bendamustina, rituximab y acalabrutinib en pacientes ≤70 años con linfoma de células del manto sin tratamiento. Leucemia mieloide aguda AML19: Estudio que realizó una comparación aleatorizada de CPX-351 y FLAG-Ida en pacientes con leucemia mieloide aguda de alto riesgo/síndrome mielodisplásico (SMD) y mutaciones genéticas relacionadas con SMD. Fecha de grabación: 14 de enero de 2025. Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.
"In B cell malignancies, BTKi inhibits that BTK enzyme which is very upstream. It tells NF-κB to stop signaling into the nucleus and then inhibits proliferation and survival of B cells." Puja Patel, PharmD, BCOP, Clinical Oncology Pharmacist at Northwestern Medicine Cancer Center at Delnor Hospital in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about BTK inhibitors. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1.0 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the BTK inhibitor drug class. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ Pharmacology 101 series ONS Voice articles: BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia FDA Grants Accelerated Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Ibrutinib Is the First Anticancer Agent to Be Negotiated for Medicare Drug Pricing Oncology Drug Reference Sheet: Pirtobrutinib Oncology Drug Reference Sheet: Zanubrutinib ONS books: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Journal of Oncology Nursing article: B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management ONS courses: ONS Cancer Biology™ ONS/ONCC Chemotherapy Immunotherapy Certificate™ Safe Handling Basics ONS Guidelines™ and Symptom Interventions: Chemotherapy-Induced Diarrhea Prevention of Bleeding Prevention of Infection: General ONS Learning Library: Oral Anticancer Medication ONS/NCODA/HOPA/ACCC's Oral Chemotherapy Education Sheets Other resources: Advanced Practice Providers Oncology Summit Ash Publications article: Managing Toxicities of Bruton Tyrosine Kinase Inhibitors Blood Advances article: BTK Inhibitors in CLL: Second-Generation Drugs and Beyond CLL Society Fact Sheets International Journal of Molecular Sciences article: Bruton's Tyrosine Kinase Inhibitors: Recent Updates National Cancer Institute article: Two Drugs Show Efficacy against Common Form of Leukemia National Comprehensive Cancer Network Guidelines for Patients: Chronic Lymphocytic Leukemia National Study of Lymphoma (University of Oxford network site-specific group— Hematology) NCODA's Positive Quality Intervention resources Pharmacy Times BTK Inhibitor Comparison Charts ScienceDirect article: Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse The Video Journal of Hematology and Hematological Oncology To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “1952 we have the discovery by Colonel Ogden Bruton of that severe immunodeficiency due to lack of B-cell maturation, and next linked to e-gamma globular anemia. In 1993, we had Professor Vetrie and colleagues discover that this was actually due to mutation in a kinase, and they called that BTK. And then in 1993 was a discovery of our first BTKi inhibitor in the lab setting, and that's called LFM-A13. It wasn't until 2013, so that's 20 years after BTK kinase was discovered, where ibrutinib was our first-in-class BTK inhibitor, and the success of ibrutinib really promoted the exploration of second- and third-generation BTKis.” TS 6:24 “It's thought that BTK and other members in the pathway are constitutively phosphorylated, which just means they're spontaneously on. This leads to this uncontrolled activation of NF- κB signaling and thus uncontrolled proliferation and suppression of apoptosis. So, these B cells are rapidly dividing, but they're not functioning like they're supposed to be, meaning they won't differentiate, or, you know, they won't grow up to be either a plasma cell, like we talked about, or a memory B cell. They've been hacked.” TS 10:11 “This class is generally called—if you have to think of an umbrella term—it's just called targeted small molecule therapies. Now a subclass is BTKi or Bruton tyrosine kinase inhibitors. So, we're really shifting away from the use of cytotoxic chemotherapy, which is kind of designed to indiscriminately destroy rapidly dividing cells, to a more precise approach of targeting cells based on specific molecular changes in tumor DNA.” TS 13:47 “Cardiac toxicity can manifest as atrial fibrillation. And here I'll specifically talk about ibrutinib values because we have the most data with it, and the numbers actually get better with second- and third-generation BTKis. So frequency: Grade 1–2 atrial fibrillation was reported in 12%–15% of patients on Ibrutinib. And grade 3 AFib is 3%–5%. The onset, median onset is 8–13 months.” TS 20:23 “For nurses, they should really advise their patients that the caliber of headaches are easily managed and they will decrease over time over a period of four weeks. This is an upfront conversation reassuring the patient that this is not a long-term side effect.” TS 33:47 “One aspect that was being discussed at length was kind of identifying biases and then methods to neutralize those biases. So, I think first you have to identify what your bias could be toward BTK, maybe it's age or comorbidities or side-effect profile. And then, how can we mitigate our own biases is kind of the solution part to that.” TS 46:26
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:Contemporary treatment paradigms for patients with CLLSafety and efficacy of current regimensMolecular testing, including when and how to test for BTK inhibitor resistanceConsidering BTK inhibitor resistance when sequencing therapy Program faculty:Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolLeader, Lymphoma ProgramDana-Farber/Harvard Cancer CenterDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsLindsey Roeker, MDAssistant AttendingCLL Program DirectorDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkResources:To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitorsConsiderations in therapy selection for previously treated CLLNovel strategies for treating CLL Presenters:Danielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies and Cellular TherapyDuke Cancer InstituteDurham, North CarolinaBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramStaff Physician, Department of Hematology and Medical OncologyTaussig Cancer InstituteCleveland ClinicCleveland, OhioDeborah Stephens, DOAssociate ProfessorDirector of the CLL ProgramLineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel Hill, North CarolinaContent based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.Link to full program including downloadable slides: https://bit.ly/49YxtSq
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
Summary: Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights: Nirogacestat (Ogsiveo) For Desmoid Tumors: Nirogacestat is the first FDA-approved drug for treating progressing desmoid tumors in adults, offering a significant improvement in response rate compared to placebo in a major trial. Pirtobrutinib (Jaypirca) in CLL/SLL: The FDA granted accelerated approval for pirtobrutinib to treat adult patients with CLL/SLL who have undergone at least two prior therapies, with its effectiveness based on response rates from the BRUIN trial. Enfortumab Vedotin (Padcev) With Pembrolizumab (Keytruda) for Urothelial Cancer: The FDA is reviewing a combination treatment of enfortumab vedotin and pembrolizumab for urothelial cancer under priority review, showing significant improvement in survival rates compared to chemotherapy in a Phase 3 study. Lisocabtagene Maraleucel (Breyanzi) for CLL/SLL: The FDA is reviewing lisocabtagene maraleucel for expanded use in treating CLL/SLL patients who have relapsed after BTKi and BCL2i treatments, based on positive results from the TRANSCEND CLL 004 study. Xanomeline-trospium (KarXT) for Schizophrenia: The FDA is considering xanomeline-trospium for treating schizophrenia, with potential benefits over traditional treatments in reducing common antipsychotic side effects, based on the EMERGENT program results. Roflumilast Cream for Atopic Dermatitis: The FDA is reviewing roflumilast cream for treating atopic dermatitis in adults and children, supported by positive results from the INTEGUMENT-1 and INTEGUMENT-2 studies, with a potential for simplification in disease control. See the full write ups for today's episode at nascentmc.com/podcast Intro and outro music Garden Of Love by Pk jazz Collective
In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side effects one has to keep in mind, and much more.
Dr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.